Keyphrases
Placebo
100%
Randomized Double-blind
100%
Carboplatin
100%
Paclitaxel
100%
Phase II Trial
100%
Advanced Ovarian Cancer
100%
ENGOT
100%
Trebananib
100%
Placebo Groups
33%
Progression-free Survival
26%
Angiopoietin
13%
Angiopoietin-2
13%
Fatal Adverse Events
13%
Hazard Ratio
6%
Physical Health
6%
Anemia
6%
Neutropenia
6%
Median Progression-free Survival
6%
Platelet Count
6%
Ovarian Cancer
6%
Maintenance Therapy
6%
First-line Therapy
6%
Angiogenesis
6%
Serum Concentration
6%
Obstetrics
6%
International Federations
6%
Cancer Center
6%
Patient Demographics
6%
Serious Adverse Events
6%
Phase III Clinical Trial
6%
One Dose
6%
Concentration-time Curve
6%
Tyrosine Kinase Receptor
6%
Treatment-related Adverse Events
6%
Vascular Remodeling
6%
Health Degradation
6%
Leukopenia
6%
Intention-to-treat
6%
Primary Peritoneal
6%
Treatment-related
6%
Hospital Center
6%
ECOG Performance Status
6%
Safety Analysis
6%
Survival Events
6%
Block Size
6%
Lung Infection
6%
Fallopian Tube Cancer
6%
Block Method
6%
Amgen
6%
Permuted Block
6%
Peritoneal Cancer
6%
Safety Signal
6%
Angiogenesis Inhibition
6%
Neutropenic Enterocolitis
6%
Primary Fallopian Tube Cancer
6%
Peptibody
6%
Medicine and Dentistry
Placebo
100%
Carboplatin
100%
Paclitaxel
100%
Ovarian Cancer
100%
Trebananib
100%
Progression Free Survival
33%
Adverse Event
26%
Angiopoietin 1
13%
Angiopoietin 2
13%
Malignant Neoplasm
6%
Clinical Trial
6%
Hazard Ratio
6%
Neutropenia
6%
Anemia
6%
Obstetrics
6%
Biopsy
6%
Platelet
6%
Angiogenesis
6%
Gynecology
6%
Intention-to-Treat Analysis
6%
Maintenance Therapy
6%
Patient Population
6%
Plasma Concentration-Time Curve
6%
Antiangiogenic Activity
6%
Tyrosine Kinase Receptor
6%
Vascular Remodeling
6%
Deterioration
6%
Leukopenia
6%
Lung Infection
6%
Fallopian Tube
6%
Colitis
6%
Electrocorticography
6%
Fallopian Tube Cancer
6%
Peritoneum Cancer
6%
Pharmacology, Toxicology and Pharmaceutical Science
Placebo
100%
Ovary Cancer
100%
Paclitaxel
100%
Carboplatin
100%
Trebananib
100%
Progression Free Survival
33%
Adverse Event
26%
Malignant Neoplasm
13%
Angiopoietin 1
13%
Angiopoietin 2
13%
Clinical Trial
6%
Anemia
6%
Neutropenia
6%
Tyrosine Kinase Receptor
6%
Vascular Remodeling
6%
Colitis
6%
Deterioration
6%
Lung Infection
6%
Peritoneum Cancer
6%
Leukopenia
6%